Could an antidepressant ease IBD disability and anxiety?
NCT ID NCT07431606
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This study tests whether duloxetine, a medication that affects brain signals, can reduce disability and psychological distress in adults with inflammatory bowel disease (IBD). About 32 participants will take duloxetine for a period, and researchers will measure changes in anxiety, depression, and daily functioning. The goal is to see if this approach is feasible, safe, and helpful for managing IBD-related symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLAMMATORY BOWEL DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Amniotic cell secretions may fight gut inflammation and scarring — a lab study puts them to the test
- Could a diet change calm IBD by reshaping gut bacteria?
- Can a peer coach help young people take control of their chronic illness?
- Scientists hunt for hidden clues to inflammatory bowel disease
- Could skipping random biopsies during colonoscopy be just as safe for IBD patients?
- Can IBD patients safely stretch their infusion schedule? new study tests two strategies